Literature DB >> 12529036

Anti-DNA antibodies--overview of assays and clinical correlations.

A Rahman1, F Hiepe.   

Abstract

Many authors have studied the links between levels of anti-dsDNA antibodies and disease activity in patients with SLE. Interpretation of these studies must take into account the facts that there are a range of possible assays for anti-dsDNA and a number of indices available for assessing disease activity. A recent study compared levels of various autoantibodies with organ specific disease activity assessed during the British Isles Lupus Assessment Group (BILAG) index. Anti-dsDNA and anti-heparan sulphate levels were more likely to be raised in patients with renal than non-renal disease. Some anti-DNA antibodies are actually anti-nucleosome antibodies, which lose DNA reactivity when purified under dissociating conditions. Patients with SLE have significantly increased levels of nucleosomes in their sera compared with healthy controls. In patients with SLE, reduced clearance of nucleosomes released from apoptotic cells may induce the formation of anti-nucleosome antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529036     DOI: 10.1191/0961203302lu313rp

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Systemic lupus erythematosus: from genes to organ damage.

Authors:  Vasileios C Kyttaris
Journal:  Methods Mol Biol       Date:  2010

2.  Markers of acute neuropsychiatric systemic lupus erythematosus: a multidisciplinary evaluation.

Authors:  Essam A Abda; Zahraa I Selim; Moustafa E M Radwan; Nagham M Mahmoud; Omar M Herdan; Khalid A Mohamad; Sherifa A Hamed
Journal:  Rheumatol Int       Date:  2012-10-12       Impact factor: 2.631

3.  Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Jasmine Arrington; Rachel A Mikolaitis; Tammy O Utset; Meenakshi Jolly; Mary K Crow; Andrew D Skol; Timothy B Niewold
Journal:  Arthritis Res Ther       Date:  2010-07-26       Impact factor: 5.156

4.  Anti-dsDNA antibodies in Brazilian patients of mainly African descent with systemic lupus erythematosus: lack of association with lupus nephritis.

Authors:  A M Atta; M M Pereira; M Santiago; M L B Sousa-Atta
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

5.  Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus.

Authors:  Robert Biesen; Cornelia Dähnrich; Anke Rosemann; Fidan Barkhudarova; Thomas Rose; Olga Jakob; Anne Bruns; Marina Backhaus; Winfried Stöcker; Gerd-Rüdiger Burmester; Wolfgang Schlumberger; Karl Egerer; Falk Hiepe
Journal:  Arthritis Res Ther       Date:  2011-02-10       Impact factor: 5.156

6.  Complexes of DNA with fluorescent dyes are effective reagents for detection of autoimmune antibodies.

Authors:  Ivana Domljanovic; Annika Carstens; Anders Okholm; Jørgen Kjems; Christoffer Tandrup Nielsen; Niels H H Heegaard; Kira Astakhova
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

Review 7.  The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

8.  High Avidity dsDNA Autoantibodies in Brazilian Women with Systemic Lupus Erythematosus: Correlation with Active Disease and Renal Dysfunction.

Authors:  Rodrigo C Oliveira; Isabela S Oliveira; Mittermayer B Santiago; Maria L B Sousa Atta; Ajax M Atta
Journal:  J Immunol Res       Date:  2015-10-25       Impact factor: 4.818

Review 9.  Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Kamini Devi Boodhoo; Sijia Liu; Xiaoxia Zuo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.